Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2021 Jul 14.
Published in final edited form as: Chem Commun (Camb). 2017 Jun 29;53(53):7238–7241. doi: 10.1039/c7cc02494k

Rapid Synthesis of Bicyclic Lactones via Palladium-Catalyzed Aminocarbonylative Lactonizations

Xianglin Yin a, Haroon Mohammad b, Hassan Eldesouky b, Ahmed A Hassan b, Mohamed N Seleem b,c, Mingji Dai a,c
PMCID: PMC8279068  NIHMSID: NIHMS1713868  PMID: 28492641

Abstract

A novel and efficient palladium-catalyzed aminocarbonylative lactonization of alkyne amino alcohols has been developed to provide rapid access of various bicyclic lactones especially dihydropyrrole-fused furanones, which are novel structures and haven’t been explored in biological and medicinal settings. This method can also be used to access β-lactone product such as 16. Preliminary biological evaluations revealed that compounds 13h and 13s demonstrated promising activity against Clostridium difficile and compounds 13h, 13k, 13s, and 16b showed activity against several important fungal pathogens.

Graphical Abstract

Novel palladium-catalyzed aminocarbonylative lactonizations have been developed to synthesize bicyclic lactones with antibacterial and antifungal activities.

graphic file with name nihms-1713868-f0001.jpg


Our recent efforts1-3 in developing tandem palladium-catalyzed carbonylation reactions4-8 for complex natural product synthesis have resulted in a novel method to access oxaspirolactones from hydroxyl cyclopropanol starting materials (Figure 1A).2 We envisioned that this new synthetic capability could be potentially used to synthesize oxaspirolactone 5, an important precursor for the total syntheses of stemofoline alkaloids (cf. 4).9-14 We proposed a tandem process to prepare 5 from 7 via an intramolecular Mannich reaction and ketalization. Compound 7 could be derived from hydroxyl cyclopropanol 8 via the palladium-catalyzed carbonylative oxaspirolactonization we have developed. Compound 8 could be synthesized from dihydropyrrole-fused furanone 10. In order to quickly access 10, we envisioned another palladium-catalyzed aminocarbonylative lactonization of alkyne amino alcohol derivative 11. Surprisingly, there was no documented synthesis of dihydropyrrole-fused furanone (cf. 10), which turned out to be a novel scaffold. Their potential biological activities and use in medicinal chemistry remain unknown. Therefore, we decided to develop and generalize the proposed palladium-catalyzed aminocarbonylative lactonizations to provide expedient avenues toward dihydropyrrole-fused furanones.

Figure 1.

Figure 1.

Background and research design

Significant advances have been made in the area of metal-catalyzed carbonylation of alkynes.15 In 1979, Murray and Norton reported an elegant palladium-catalyzed carbonylation of homopropargylic alcohols to synthesize α-methylene γ-lactones.16-17 Since then, many palladium-catalyzed cyclocarbonylations of alkynes have been reported. Notably, Alper and co-workers reported carbonylative syntheses of 2(5H)-furanones from pargylic alcohols;18-20 Yang,21-25 Akita,26 Gabriele27-29 and others30-34 have reported oxy or amino-palladation-alkoxycarbonylation of alkynes to synthesize various heterocylces. Despite these progresses, an intramolecular aminopalladation-carbonylative lactonization of alkyne amino alcohols of type 11 to synthesize dihydropyrrolefused furanones (cf. 10) has not been reported. Herein, we describe elements of our recent efforts in developing such transformations to rapidly construct dihydropyrrole-fused furanones, which could not only facilitate total syntheses of complex natural products such as the stemofoline alkaloids, but also provide novel molecules for therapeutic development.

Our investigation started with model substrate 12a (Table 1), which was readily prepared via 1,2-addition of acetylide to hydrocinnamaldehyde (see the Supporting Information). When the commonly used carbonylation catalyst PdCl2 was used in combination with 2,2-bipyridine ligand A, no desired product 13a was obtained. We hypothesized that a more cationic and electron-deficient palladium catalyst should function better to activate the triple bond for the aminopalladation step than the neutral PdCl2 catalyst. Thus, Pd(tfa)2 was explored next. To our delight, the desired product 13a was produced in 63% yield with p-benzoquinone (BQ, 1.5 equiv.) as oxidant and MeCN as solvent. We then investigated the effect of different ligands and several bipyridine and 1,10-phenanthroline-based ligands (entry 3-6) were evaluated. These ligands are either the same as ligand A or slightly less effective, but are much more effective than BOX-ligand F (entry 8). Bidentate phosphine ligand Xantphos (entry 7) turned off the reaction almost completely and only a trace amount of 13a was obtained. We further found that a 1:2 ratio of the palladium catalyst and the ligand is not as good as 1:1. Increasing the amount of BQ from 1.5 equiv. to 3.0 equiv. (entry 11) made the reaction messier with 51% yield of the desired product and decreasing the amount to 1.0 equiv. slightly reduced the reaction yield (61%, entry 12). Adding base such as Cs2CO3 was detrimental (entry 13) and increasing the carbon monoxide pressure to 7 atm showed inhibitory effect (entry 14). To further improve the reaction yield, we explored the more electron deficient Pd(OTf)2 (0.1 equiv.) complex generated from a combination of PdCl2(MeCN)2 and AgOTf (1:2 ratio). The yield did increase to 72% (entry 15). Ligand G (entry 16, 81% yield) was found to be superior to ligand C (entry 4) and ligand H (entry 16). Pd(neoc)2(OAc)2(OTf)2, a cationic dimeric palladium complex developed by the Waymouth lab35 also worked for this transformation but with reduced reaction yield. While CuCl2 as oxidant was deleterious, 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) increased the yield to 90% (entry 20). Interesting, when the nitrogen-protecting group was changed to Boc (12a’), even the optimized reaction conditions didn’t give any desired product 13a’ (entry 21). When MeOH was used as solvent with Pd(tfa)2(DMSO)2 as catalyst and BQ as oxidant, product 14 was produced in 24% yield (entry 22), which indicates that with Boc-protected substrate, the aminopalladation and alkoxycarbonylation steps could take place, but not the lactonization step. These results suggest that the formation of the furanone ring is the problematic step presumably due to pseudo-A(1,3) interaction between the Boc group and the alkyl side chain.

Table 1.

Reaction condition optimizations.

graphic file with name nihms-1713868-t0005.jpg
Entry Reaction Conditions (equiv.) Yielda (%)
1 PdCl2 (0.1), A (0.1), BQ (1.5), PG = Ts 0%
2 Pd(tfa)2 (0.1), A (0.1), BQ (1.5), PG = Ts 63%
3 Pd(tfa)2 (0.1), B (0.1), BQ (1.5), PG = Ts 58%
4 Pd(tfa)2 (0.1), C (0.1), BQ (1.5), PG = Ts 63%
5 Pd(tfa)2 (0.1), D (0.1), BQ (1.5), PG = Ts 58%
6 Pd(tfa)2 (0.1), E (0.1), BQ (1.5), PG = Ts 53%
7 Pd(tfa)2 (0.1), Xantphos (0.1), BQ (1.5), PG = Ts trace
8 Pd(tfa)2 (0.1), F (0.1), BQ (1.5), PG = Ts 33%
9 PdCl2(MeCN)2 (0.1), E (0.1), BQ (1.5), PG = Ts 0%
10 Pd(tfa)2 (0.1), C (0.2), BQ (1.5), PG = Ts 41%
11 Pd(tfa)2 (0.1), C (0.1), BQ (3.0), PG = Ts 51%
12 Pd(tfa)2 (0.1), C (0.1), BQ (1.0), PG = Ts 61%
13 Pd(tfa)2 (0.1), C (0.1), BQ (1.0), PG = Ts, Cs2CO3 (1.0) 0%
14 Pd(tfa)2 (0.1), C (0.1), BQ (1.5), PG = Ts, CO (7 atm) 31%
15 PdCl2(MeCN)2 (0.1)/AgOTf (0.2), C (0.1), BQ (1.5), PG = Ts 72%
16 PdCl2(MeCN)2 (0.1)/AgOTf (0.2), G (0.1), BQ (1.5), PG = Ts 81%
17 PdCl2(MeCN)2 (0.1)/AgOTf (0.2), H (0.1), BQ (1.5), PG = Ts 42%
18 Pd(neoc)2(OAc)2(OTf)2 (0.1), BQ (1.5), PG = Ts 69%
19 PdCl2(MeCN)2 (0.1)/AgOTf (0.2), G (0.1), CuCl2 (1.5), PG = Ts 0%
20 PdCl2(MeCN)2 (0.1)/AgOTf (0.2), G (0.1), DDQ (1.5), PG = Ts 90%
21 PdCl2(MeCN)2 (0.1)/AgOTf (0.2), G (0.1), DDQ (1.5), PG = Boc 0%
22 Pd(tfa)2(DMSO)2 (0.1), BQ (1.5), PG = Boc, MeOH 24%b
a.

Isolated yield

b.

Yield of 14 with MeOH as solvent.

b.

With optimized reaction conditions established, the substrate scope of this new aminocarbonylative lactonization method was assessed (Table 2). A variety of hydropyrrole-fused furanones can be prepared. In general, for secondary propargylic alcohols with an alkyl substituent, the reaction yield is excellent (cf. 13a-d). The yield for secondary propargylic alcohols with an aryl substituent dropped slightly (cf. 13f-g) or significantly (cf. 13e, 13i-j) presumably due to the ease of oxidizing the secondary alcohol to a ketone and other undesired reaction pathways. Primary proparylic alcohol substrate gave modest yield of the desired hydropyrrole-fused furanone product (cf. 13k). Notably, sterically hindered tertiary alcohols (13i-t) are excellent substrates and high yields were obtained except for the case of 13q. Tricyclic products 13l-o and 13r-t containing a spirocyclic ring system were produced in excellent yield. The structure of 13o was unambiguously confirmed by X-ray analysis.36 Due to the mild reaction conditions, functional groups such as sulfonamide, Boccarbamate, bromide, and nitro group are well tolerated. The reaction can also be conducted in gram-scale (13q).

Table 2.

Substrate Scope.

graphic file with name nihms-1713868-t0007.jpg

We then prepared substrate 15 and wondered the possibility of forming a 5,6-fused furanone product (cf. 17). With one carbon added between the nitrogen nucleophile and the triple bond, in addition to the expected 6-endo-dig aminopalladation, a 5-exo-dig amino-palladation becomes a potential competing pathway. If the latter occurs, we would be expecting a strained β-lactone product (cf. 16). Interestingly, under the optimal reaction conditions for the formation of 5,5-fused furanones, no fused product 17 was identified in the reaction mixture; instead, β-lactone product 16 was produced in 40% (R = Ph) or 18% (R = Me) yield.37 The structure and double bond geometry of 16a were unambiguously validated by X-ray analysis.36

Mechanistically, as shown in Figure 3, after ligand exchange, a hydroxyl group-directed activation of the alkyne with the Pd(II) catalyst would trigger a 5-endo-dig anti-aminopalladation to form the dihydropyrrole ring and produce vinyl-palladium species 19 from 18. Carbon monoxide migratory insertion followed by lactonization would lead to product 13 and a Pd(0) catalyst. The latter would be oxidized to a Pd(II) catalyst by DDQ to continue the next catalytic cycle. For the formation of 16, a 6-endo-dig anti-aminopalladation overrides a 5-exo-dig amino-palladation. The trans double bond geometry of 16 supported the anti-aminopalladation process over a syn-aminopalladation process.

Figure 3.

Figure 3.

Proposed catalytic cycle.

Due to the structural novelty of the aminocarbonylative lactonization products, we evaluated them against several important bacterial, yeast and mold pathogens (see the Supporting Information). Our preliminary results showed that compounds 13h and 13s exhibited promising activity against toxigenic strains of Clostridium difficile with 128 μM and 64 μM minimum inhibitory concentration (MIC). Interestingly, these two compounds did not show side effect on the beneficial intestinal microflora and were nontoxic to Caco-2-cell lines up to 256 μM. Compounds 13h, 13k, 13s, and 16b showed activity against several important fungal pathogens including strains of Candida albicans, Candida glabrata, Candida krusei, Cryptococcus gattii, Cryptococcus neoformans, Aspergillus fumigatus, Aspergillus niger, and Aspergillus brasiliensis with 64 to 128 μM MIC values.

In summary, we have developed an efficient palladium-catalyzed aminocarbonylative lactonization of alkyne amino alcohols to synthesize various novel dihydropyrrole-fused furanones. This method can also be used to access β-lactone product such as 16, another novel scaffold with potential biological functions. Our preliminary biological evaluations have identified several compounds including 13h, 13k, 13s, and 16b with promising antibacterial and antifungal activity. We are currently using this new synthetic capability to facilitate total syntheses of complex natural products as well as preparing analogues of the antibacterial and antifungal lead compounds to improve potency and physicochemical properties for new therapeutic development.

Supplementary Material

1

Figure 2.

Figure 2.

Formation of β-lactone product.

Acknowledgments

This work was financially supported by NSF CAREER Award (1553820). The NIH P30CA023168 supported shared NMR resources to Purdue Center for Cancer Research. The XRD data is collected on a new single crystal X-ray diffractometer supported by the National Science Foundation through the Major Research Instrumentation Program under Grant No. CHE 1625543.

Notes and references

  • 1.Bai Y, Shen X, Li Y and Dai MJ, J. Am. Chem. Soc, 2016, 138, 10838–10841. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Davis DC, Walker KL, Hu C, Zare RN, Waymouth RM and Dai MJ, J. Am. Chem. Soc, 2016, 138, 10693–10699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Bai Y, Davis DC and Dai MJ, Angew. Chem. Int. Ed, 2014, 53, 6519–6522. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Bai Y, Davis DC and Dai MJ, J. Org. Chem, 2017, 82, 2319–2328. [DOI] [PubMed] [Google Scholar]
  • 5.Wu X-F, Neumann H and Beller M, Chem. Rev, 2013, 113, 1–35. [DOI] [PubMed] [Google Scholar]
  • 6.Gehrtz PH, Hirschbeck V, Ciszek B and Fleischer I, Synthesis, 2016, 48, 1573–1596. [Google Scholar]
  • 7.Gabor K, Chem. Rev, 2001, 101, 3435–3456. [DOI] [PubMed] [Google Scholar]
  • 8.Barnard CFJ, Organometallics, 2008, 27, 5402–5422. [Google Scholar]
  • 9.Pilli RA, Rosso GB and de Oliveira MCF, Nat. Prod. Rep, 2010, 27, 1908–1937. [DOI] [PubMed] [Google Scholar]
  • 10.Kende AS, Smalley TL Jr. and Huang H, J. Am. Chem. Soc, 1999, 121, 7431–7432. [Google Scholar]
  • 11.Brüggemann M, McDonald AI, Overman LE, Rosen MD, Schwink L and Scott JP J. Am. Chem. Soc, 2003, 125, 15284–15285. [DOI] [PubMed] [Google Scholar]
  • 12.Fang C, Shanahan CS, Paull DH and Martin SF, Angew. Chem. Int. Ed, 2012, 51, 10596–10599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Ideue E, Shimokawa J and Fukuyama T, Org. Lett, 2015, 17, 4964–4967. [DOI] [PubMed] [Google Scholar]
  • 14.Qiang P-Q, Huang S-Y, Gao L-H, Mao Z-Y, Chang Z and Wang A-E, Chem. Commun, 2015, 51, 4576–4578. [DOI] [PubMed] [Google Scholar]
  • 15.For a review: Quintero-Duque S, Dyballa KM and Fleischer I, Tetrahedron Lett. 2015, 56, 2634–2650. [Google Scholar]
  • 16.Murray TF and Norton JR J. Am. Chem. Soc, 1979, 101, 4107–4119. [Google Scholar]
  • 17.Murray TF, Samsel EG, Varma V and Norton JR J. Am. Chem. Soc, 1979, 103, 7520–7528. [Google Scholar]
  • 18.Ali BE and Alper H J. Org. Chem, 1991, 56, 5357–5360. [Google Scholar]
  • 19.Yu W-Y and Alper H J. Org. Chem, 1993, 58, 5684–5687. [Google Scholar]
  • 20.Xiao W-J and Alper H J. Org. Chem, 1997, 62, 3422–3423. [Google Scholar]
  • 21.Nan Y, Miao H and Yang Z, Org. Lett. 2000, 2, 297–299. [DOI] [PubMed] [Google Scholar]
  • 22.Hu Y and Yang Z, Org. Lett. 2001, 3, 1387–1390. [DOI] [PubMed] [Google Scholar]
  • 23.Liao Y, Reitman M, Zhang Y, Fathi R and Z. Yang Org. Lett 2002, 4, 2607–2609. [DOI] [PubMed] [Google Scholar]
  • 24.Hu Y, Zhang Y, Yang Z and Fathi R, J. Org. Chem 2002, 67, 2365–2368. [DOI] [PubMed] [Google Scholar]
  • 25.Liao Y, Smith J, Fathi R and Yang Z, Org. Lett 2005, 7, 2707–2709. [DOI] [PubMed] [Google Scholar]
  • 26.Kato K, Motodate S, Mochida T, Kobayashi T and Akita H Angew. Chem. Int. Ed, 2009, 48, 3326–3328. [DOI] [PubMed] [Google Scholar]
  • 27.Gabriele B, Mancuso R, Maltese V, Veltri L and Salerno G, J. Org. Chem, 2012, 77, 8657–8668. [DOI] [PubMed] [Google Scholar]
  • 28.Gabriele B, Veltri L, Mancuso R, Salerno G and Costa M, Eur. J. Org. Chem, 2012, 2549–2559. [Google Scholar]
  • 29.Gabriele B, Salerno G, Plastina P, Costa M and Crispini, Adv. Synth. Catal, 2004, 346, 351–358. [Google Scholar]
  • 30.Ogawa A, Kuniyasu H, Sonoda N and Hirao T, J. Org. Chem, 1997, 62, 8361–8365. [DOI] [PubMed] [Google Scholar]
  • 31.Tamaru Y, Hojo M and Yoshida Z.-i, J. Org. Chem, 1991, 56, 1099–1105. [Google Scholar]
  • 32.Li J-H, Tang S and Xie Y-X, , J. Org. Chem, 2005, 70, 477–479. [DOI] [PubMed] [Google Scholar]
  • 33.Copéret C, Sugihara T, Wu G, Shimoyama I and Negishi E.-i, J. Am. Chem. Soc, 1995, 117, 3422–3431. [Google Scholar]
  • 34.Zhao L and Lu X, Angew. Chem. Int. Ed, 2002, 41, 4343–4345. [DOI] [PubMed] [Google Scholar]
  • 35.Conley NR, Labios LA, Pearson DM, McCrory CCL and Waymouth RM, Organometallics, 2007, 26, 5447–5453. [Google Scholar]
  • 36.CCDC 1540287 and CCDC 1540288 contain the supplementary crystallographic data for compounds 13o and 16a, respectively.
  • 37.Ma S, Wu B and Zhao S, Org. Lett. 2003, 5, 4429–4432. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

1

RESOURCES